Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRA: Lotilaner for Demodex Blepharitis in China
NCT05629390Phase 3Completed
- Sponsor
- LianBio
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Demodex blepharitis (DB) comparing Lotilaner (TP-03) with Vehicle (2 arms). Primary endpoints: Proportion of participants cured based on collarette score of 0 at 43 days, Proportion of participants with Demodex eradication at 43 days and 1 more. Started Oct 2022; status: completed.
02
Drugs
lotilaner
03
Conditions
Demodex blepharitis (DB)
Beyond the preview
Go deeper on NCT05629390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629390.